H.R. 5155 (108th): Free Market Drug Act

Sep 28, 2004 (108th Congress, 2003–2004)
Died (Referred to Committee)
Dennis Kucinich
Representative for Ohio's 10th congressional district
Read Text »
Last Updated
Sep 28, 2004
11 pages

This bill was introduced on September 28, 2004, in a previous session of Congress, but was not enacted.

Introduced Sep 28, 2004
Referred to Committee Sep 28, 2004
Full Title

To establish the National Institute for Biomedical Research and Development.


No summaries available.

9 cosponsors (9D) (show)

House Energy and Commerce


The committee chair determines whether a bill will move past the committee stage.

Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.


Get a bill status widget for your website »


Click a format for a citation suggestion:


H.R. stands for House of Representatives bill.

A bill must be passed by both the House and Senate in identical form and then be signed by the president to become law.

The bill’s title was written by its sponsor.

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.

Free Market Drug Act - Establishes the National Institute for Biomedical Research and Development to provide for the development of drugs, biological products, and devices to: (1) increase the number and medical efficacy of drugs, biological products, and devices on the market; and (2) make the drugs, biological products, and devices available to the public at reasonable prices.
Requires the Director of the Institute to:
(1) monitor the results of certain research to identify discoveries that, if subjected to appropriate research and development activities, may be suitable for approval by the Food and Drug Administration (FDA) as drugs, biological products, or devices for use in humans (candidate discoveries);
(2) identify candidate discoveries and carry out appropriate research and development regarding such discoveries;
(3) establish, review, and revise a plan for the development, testing, and manufacture of candidate discoveries through the Institute;
(4) establish priorities among candidate discoveries; and
(5)) maintain an Internet site to make available to the public information on activities under this Act.
Allows the Director to identify a discovery as a candidate discovery only if the Federal Government holds, or can reasonably be expected to obtain, a patent on the discovery. Prohibits the Director from transferring ownership of such patent to any non-Federal entity.
Allows civil suits to protect Federal ownership of patents.
Requires the Director to: (1) grant non-exclusive licenses for the commercial marketing of FDA-approved candidate discoveries; (2) establish Federal laboratories to carry out this Act; and (3) establish a fund to provide cash awards for making significant advances in knowledge regarding a disease, disorder, or other health condition.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.

No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

Use the comment space below for discussion of the merits of H.R. 5155 (108th) with other GovTrack users.
Your comments are not read by Congressional staff.

comments powered by Disqus